Abstract
Selective inhibitors of cyclic nucleotide phosphodiesterases (PDEs) have been widely studied as therapeutic agents for the treatment of various human diseases. Three-dimensional structures are essential for the design of highly selective inhibitors, but their availability is limited by the speed of crystallization. We describe crystallization of the catalytic domains of the unligated PDE4B2B, rolipram-bound PDE4D2, and 3-isobutyl-1-methylxanthine-bound PDE5A1 using the methods of vapor diffusion and microdialysis. We also briefly describe general methods of protein crystallization to provide a background to readers outside of the crystallographic field. Finally, we discuss detailed procedures for and pitfalls of the crystallization of PDEs, which may be valuable for crystallization of other PDE members.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Barnette, M. S. and Underwood, D. C. (2000) New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr. Opin. Pulm. Med. 6, 164–169.
Huang, Z., Ducharme, Y., Macdonald, D., and Robichaud, A. (2001) The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. 5, 432–438.
Giembycz, M. A. (2002) Development status of second generation PDE 4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 57, 48–64.
Spina, D. (2003) Theophylline and PDE4 inhibitors in asthma. Curr. Opin. Pulm. Med. 9, 57–64.
Reilly, M. P. and Mohler, E. R. III. (2001) Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 35, 48–56.
Corbin, J. D. and Francis, S. H. (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56, 453–459.
Torphy, T. J. (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157, 351–370.
Conti, M. and Jin, S. L. (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63, 1–38.
Soderling, S. H. and Beavo, J. A. (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12, 174–179.
Houslay, M. D. and Adams, D. R. (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1–18.
Weber, P. C. (1997) Overview of protein crystallization, in Methods in Enzymology (Carter, C. W. Jr. and Sweet, R. M., eds.), Academic, New York, pp. 13–22.
Stevens, R. C. (2000) High-throughput protein crystallization. Curr. Opin. Struct. Biol. 10, 558–563.
Juarez-Martinez, G., Steinmann, P., Roszak, A.W., Isaacs, N.W., and Cooper, J. M. (2002) High-throughput screens for postgenomics: studies of protein crystallization using microsystems technology. Anal. Chem. 74, 3505–3510.
Chayen, N. E. and Saridakis, E. (2002) Protein crystallization for genomics: towards high-throughput optimization techniques. Acta Crystallogr. D 58, 921–927.
Krupka, H. I., Rupp, B., Segelke, B. W., Lekin, T. P., Wright, D., Wu, H. C., Todd, P., and Azarani, A. (2002) The high-speed Hydra-Plus-One system for automated high-throughput protein crystallography. Acta Crystallogr. D 58, 1523–1526.
Mueller, U., Nyarsik, L., Horn, M., Rauth, H., Przewieslik, T., Saenger, W., Lehrach, H., and Eickhoff, H. (2001) Development of a technology for automation and miniaturization of protein crystallization. J. Biotechnol. 85, 7–14.
Carter, C. W. Jr. and Carter, C. W. (1979) Protein crystallization using incomplete factorial experiments. J. Biol. Chem. 254, 12,219–12,223.
Jancarik, J. and Kim, S. H. (1991) Spare matrix sampling: a screening method for crystallization of proteins. J. Appl. Crystallogr. 24, 409–411.
Xu, R. X., Hassell, A. M., Vanderwatt, D., et al. (2000) Atomic structure of PDE4: insight into phosphodiesterase mechanism and specificity. Science 288, 1822–1825.
Huai, Q., Wang, H., Sun, Y., Kim, H. Y., Liu, Y., and Ke, H. (2003) Three dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11, 865–873.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Ke, H., Huai, Q., Xu, R.X. (2005). Crystallization of Cyclic Nucleotide Phosphodiesterases. In: Lugnier, C. (eds) Phosphodiesterase Methods and Protocols. Methods In Molecular Biology™, vol 307. Humana Press. https://doi.org/10.1385/1-59259-839-0:181
Download citation
DOI: https://doi.org/10.1385/1-59259-839-0:181
Publisher Name: Humana Press
Print ISBN: 978-1-58829-314-5
Online ISBN: 978-1-59259-839-7
eBook Packages: Springer Protocols